Reconstitution of T cell immunity against EBV in the immunocompromised host by adoptive transfer of peptide-stimulated T cells after allogeneic stem cell transplantation

María Fernanda Lammoglia Cobo^{1¶}, Julia Ritter^{2¶}, Regina Gary³, Volkhard Seitz^{2,4}, Josef Mautner^{5,6}, Michael Aigner³, Simon Völkl³, Stefanie Schaffer³, Stephanie Moi³, Anke Seegebarth², Heiko Bruns³, Wolf Rösler³, Kerstin Amann⁷, Maike Büttner-Herold⁷, Steffen Hennig⁴, Andreas Mackensen³, Michael Hummel², Andreas Moosmann^{5,6&}, Armin Gerbitz^{8&*}

¹ Department of Hematology, Oncology, and Tumor Immunology, ² Institute of Pathology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

³ Department of Internal Medicine 5 – Hematology/Oncology, University Hospital Erlangen, Erlangen, Germany

⁴ HS Diagnostics GmbH, Berlin, Germany

⁵ Department of Medicine III, LMU-Klinikum, Munich, Germany

⁶ German Centre for Infection Research, Munich, Germany

⁷ Department of Nephropathology, Institute of Pathology, University of Erlangen, Erlangen, Germany

⁸ Division of Medical Oncology and Hematology, Princess Margaret Cancer Center, Toronto, Ontario, Canada

*Corresponding author

E-Mail: armin.gerbitz@uhn.ca (AG)

¶ Both authors contributed equally to this work.

& Both authors contributed equally to this work.

Abstract

Reconstitution of T cell repertoire after allogeneic stem cell transplantation is a long and often incomplete process. As a result, reactivation of Epstein-Barr virus (EBV) is a frequent complication that may be treated by adoptive transfer of donor-derived EBV-specific T cells. We generated donor-derived EBV-specific T cells by peptide stimulation and adoptively transferred them to a patient with angioimmunoblastic T-cell lymphoma (AITL), who had developed persisting high titers of EBV concomitant to relapse after transplantation. T cell receptor beta (TCR β) deep sequencing showed that the T cell repertoire of the patient early after transplantation (day 60) was strongly reduced and only very low numbers of EBV-specific T cells were detectable. Manufacturing and *in vitro* expansion of donor-derived EBV-specific T cells resulted in enrichment of EBV epitope-specific, HLA-restricted T cells. Monitoring after adoptive transfer revealed that the dominant TCR sequences from peptide-stimulated T cells persisted long-term and established an EBV-specific TCR clonotype repertoire in the host, with many of the EBV-specific TCRs present in the donor. This reconstituted repertoire was associated with immunological control of EBV and with lack of further AITL relapse.

Author summary

A characteristic feature of all herpesviruses is their persistence in the host's body after primary infection. Hence, the host's immune system is confronted with the problem to control these viruses life-long. Well-known representative of the herpesvirus group are the classic Herpes-Simplex Virus (HSV-1) and Varicella Zoster Virus (VZV, causing chicken pox); a less known representative is Epstein Barr Virus (EBV, causing mononucleosis). When the immune system is severely compromised, for example after stem cell transplantation from a foreign (allogeneic) donor, these viruses can reappear, as they are already in the host's body. Especially EBV cause life-threatening complications after stem cell transplantation and only reinforcement of the host's immune system can reestablish viral control. Here we show that *ex vivo* manufactured EBV-specific T cells can reestablish long-term control of EBV and that these cells persist in the host's body over months. These results give us a better understanding of viral immune reconstitution post-transplant and of clinically-relevant T cell populations against EBV.

Introduction

Linked to its high prevalence in adults, approximately 30-40% of patients reactivate Epstein-Barr virus (EBV) after MHC-matched allogeneic stem cell transplantation (allo-SCT), as determined by virus-specific PCR of cells of the peripheral blood [1]. Reactivation of EBV worsens outcome after allo-SCT, since it imposes the risk of EBV-associated post-transplant lymphoproliferative disease (PTLD) and is associated with malignancies such as angioimmunoblastic T cell lymphoma (AITL) [2]. AITL is a rare form of T cell non-Hodgkin Lymphoma in which concomitant EBV infection often occurs [3]. EBV appears to play a role in AITL pathogenesis and histological development [2, 4], either through EBV-infected B immunoblasts found at early AITL stages adjacent to neoplastic T cells [5–7] or infection of both cells types [8]. For this reason, EBV serostatus and viral loads serve as important prognostic factors [9, 10], especially among young patients [11].

EBV DNA load in peripheral blood is routinely monitored by polymerase chain reaction (PCR) in patients after allo-SCT to allow for pre-emptive treatment strategies [12]. Since no specific antiviral therapy is available to date, treatment of EBV-related disease in patients after allo-SCT focuses on three major strategies: (i) in-patient depletion of EBV-transformed B cells with antibodies -with depletion of other B cells as collateral damage- (ii) reduction of immunosuppression, or (iii) application of EBV-specific, donor-derived T cells [13–16].

The availability of B cell-depleting antibodies has reduced the occurrence of PTLD after allo-SCT [17], but comes with severe side effects and costs. Due to the long-term depletion of B cells, antibody generation is abolished and patients are at risk of severe infections, especially with encapsulated bacteria whose control requires antibody opsonization [18, 19]. Therefore, frequent application of intravenous immunoglobulins is necessary. Furthermore, the problem of failing immunological control of EBV is not resolved.

As an alternative strategy, several groups have focused on the development of EBV-specific T cell transfer, as reactivation of EBV is associated with use of T cell-depleted grafts or insufficient T cell reconstitution after transplantation. This approach does not bear the risk of developing *de novo* graft

versus host disease [20–24]. Adoptive transfer of natural EBV-specific T cells from EBV-positive donors has been performed and is considered overall a success due to its effectiveness and safety [23]. For patients with EBV-seronegative donors, where natural EBV-specific T cells are not available, adoptive transfer of EBV TCR-transduced T cells is a promising alternative [25–29].

We have recently described a Good Manufacturing Practice (GMP)-compliant method for the generation of CMV- and EBV-specific T cells by stimulation of G-CSF mobilized allogeneic stem cell grafts or conventional PBMC with MHC-I- and MHC-II-restricted epitope peptides derived from viral proteins [24]. We selected peptides that allow for comprehensive quality control of the product and subsequent follow-up within the patient after adoptive transfer, using flow cytometry with peptide-MHC multimers. However, little is known about the detailed structure of the EBV-specific T cell repertoire recognizing each epitope and its fate after adoptive transfer into the patient.

Here, we generated multi-epitope-specific T cells by peptide stimulation and adoptively transferred them to a patient with AITL after allo-SCT and EBV reactivation. Using high-throughput sequencing of the TCR β repertoire, we show that stimulation of T cells with EBV peptides generates a product with a TCR β repertoire that is strongly focused on EBV-specific sequences, and that this repertoire can be tracked long-term *in vivo* after adoptive transfer in the patient.

Results

Manufacturing of EBV-specific T cells

A total of 600 million conventional PBMC were stimulated with a premixed pool of defined EBV epitope peptides (1 µg/ml per peptide, Table 1), similar to our earlier procedure [24]. Peptide-stimulated cells were subsequently expanded in a closed bag system for 9 days. Fig 1A (left panel) shows the composition of the PBMC before peptide stimulation (day 0) and of the resulting cell composition after 9 days of expansion. The dominant fraction of cells in the product were CD3⁺ T cells (84.8%). B cells, NK cells and monocytes were reduced to 5.8% of all cells. Other cells (9.4%) were mainly macrophages, activated monocytes, neutrophils (all CD11b⁺, CD68⁺), and few remaining granulocytes. As shown in Fig 1A (right panel), total CD3⁺ T cell number increased from approximately 315 million to 631 million cells over the 9-day period, and a total of approximately 750 million cells were harvested.

Fig 1. Manufacture of EBV-specific T cells.

(A) Composition of the apheresis product that served as starting material (day 0) and the resulting T cell culture after stimulation with EBV peptides (day 9). Left panel: Proportions of different cell types in CD45⁺ cells (monocytes: CD14⁺SSC^{low}, NK cells: CD56⁺, B cells: CD19⁺, T cells: CD3⁺, rest of leukocytes). Right panel: Composition in absolute cell numbers. (B) Percentage of peptide-specific T cells assessed by flow cytometry using peptide-MHC multimers (RLR, HLA-A*03:01; QAK, RAK, HLA-B*08:01; YPL, HPV, EPL, HLA-B*35:01) on day 0 and day 9. (C) IFN-γ secretion of peptide-specific T cells after restimulation with single peptides on day 9, assessed by intracellular cytokine staining (neg.: unstimulated CD8⁺ T cells, pos.: stimulation of T cells with ionomycin). (D) Flow cytometric analysis of T cell memory/differentiation markers on day 0 and day 9. Plots on the right side are pre-gated on CD3⁺ cells. temra=terminally differentiated effector memory T cells (CCR7⁻ CD45RA⁺), eff/em=effector/effector memory T cells (CCR7⁻ CD45RA⁺), cm=central memory T cells (CCR7⁺ CD45RA⁻), naïve=naïve T cells (CCR7⁺ CD45RA⁺). (E) Percentage of T cell subsets within CD4⁺ and CD8⁺ T cells. (F)

Flow cytometric analysis of T cell activation markers CD25, HLA-DR and CD38 within the CD4⁺ and CD8⁺ T cell compartment.

Table 1: Peptide pool used for T cell stimulation.

label	AA Sequence	peptide length	protein	presented on HLA	reference	matched with patient
CLG	CLGGLTMV	9	LMP2	A*02:01	[30]	
GLC	GLCTLVAML	9	BMLF1	A*02:01	[31, 32]	
YVL	YVLDHLIVV	9	BRLF1	A*02:01	[33]	
FLY	FLYALALL	9	LMP2	A*02:01	[34]	
RLR	RLRAEAQVK	9	EBNA3A	A*03:01	[35]	+
RPP	RPPIFIRRL	9	EBNA3A	B*07:02	[35]	
QAK	QAKWRLQTL	9	EBNA3A	B*08:01	[36]	+
RAK	RAKFKQLL	8	BZLF1	B*08:01	[37]	+
YPL	YPLHEQHGM	9	EBNA3A	B*35:01	[36]	+
HPV	HPVGEADYFEY	11	EBNA1	B*35:01	[38]	+
EPL	EPLPQGQLTAY	11	BZLF1	B*35:01	[33]	+
PYYV	PYYVVDLSVRGM	12	BHRF1	DR*4	[39]	
VVRM	VVRMFMRRERQLPQS	14	EBNA3C	DR*11	[40]	
FGQL	FGQLTPHTKAVYQPR	15	BLLF1	DR*13	[41]	
IPQC	IPQCRLTPLSRPFG	15	EBNA1	DR*13	[42]	
TDAW	TDAWRFAMNYPRNPT	15	BNRF1	DR*15	[43]	

AA: amino acid sequence.

The T cell product was analyzed before and after peptide stimulation with peptide-MHC multimers (Fig 1B) corresponding to the six peptides of the stimulation pool that were restricted through HLAs present in transplant donor and recipient (Table 1). On day 0, 2.4 % of CD8⁺ T cells, mainly in the CCR7-negative subset, specifically bound peptide-MHC multimers. By day 9, T cells specific for five of the six epitopes had strongly expanded and now amounted to 64.6% of all CD8⁺ T cells. Two epitopes (RAK and EPL) from the immediate-early protein BZLF1 and one epitope (HPV) from the latent antigen EBNA1 were particularly dominant. Intracellular cytokine staining after restimulation demonstrated, as expected [44], that a variable proportion of CD8⁺ T cells specific for these epitopes secreted IFN- γ in response to single peptide stimulation (Fig 1C). A high proportion of IFN- γ -secreting CD8⁺ cells (13.2%, compared to 24.1% of multimer-staining cells) was seen for the EPL epitope. An increase of IFN- γ concentration and other cytokines was also detected in patient serum after adoptive transfer (S1 Fig). While more than half (53.6%) of CD3⁺ T cells of the PBMCs (day 0) had initially a naive phenotype (CCR7⁺/CD45RA⁺),

these were reduced to 15.4% on day 9 (Fig 1D). In contrast, the proportion of T cells with effector/effector memory phenotype (CCR7-/CD45RA+) changed from 22.8% to 80.0%. Separate analysis showed that T cell memory phenotypes were extensively changed in the CD8+ but hardly in the CD4+ T cell subset (Fig 1E), while expression of the activation markers CD25, HLA-DR and CD38 was also largely limited to the CD8+ subset (Fig 1F). As far as is known (and disregarding the possibility of promiscuous HLA class II restriction [45]), peptides presented on HLA-DR to CD4+ T cells and which were used for stimulation (Table 1) were not restricted for any donor or patient HLA-ABC molecule. Consequently, EBV-specific CD4+ T cells may not have been stimulated by the EBV peptide pool, and therefore memory and activation markers on CD4+ T cells were not altered.

Analysis of the TCR repertoire of the T cell product

Having demonstrated that stimulation of T cells with a pool of EBV peptides results in strong expansion of peptide-specific CD8+ effector and effector/effector-memory T cells, we next analyzed the T cell receptor β -chain (TCR β) repertoire before and after peptide stimulation. To this end, we amplified the TCR β of flow cytometry-sorted CD8+ T cells via high-throughput sequencing (HTS). For comparability, the same amount of DNA (100 ng per analysis) - representing the equivalent number of T cell rearrangements (approximately 14,500 T cells) - was employed for each library preparation. Within a first study, we were able to demonstrate that analyzing this constant amount of T cells reliably reflects T cell composition and T cell diversity [46].

Following this approach, we observed a strong change in the usage of TCR V β segments of the sorted CD8+ T cells before and after EBV peptide stimulation (Fig 2A, left panel). While the proportion of V β 19, 20, and 4 was reduced over 9 days of cultivation, we observed an expansion of V β 6 and V β 7 chains. Next, we enriched EBV epitope-specific CD8+ T cells by flow cytometry cell sorting based on peptide-MHC multimer binding on day 9. Interestingly, individual patterns of V β usage were characteristic for each EBV epitope (Fig 2A, right panel), with predominant V β 6 usage in EPL and HPV multimer-enriched CD8+ T cells, and V β 7 and V β 4 predominant in RAK-enriched T cells.

Fig 2. Global and EBV-specific TCR repertoire of the T cell product.

(A) V β usage. Left panel: Percentage of V β subgroup usage within CD8⁺ T cells before (day 0) and after (day 9) peptide stimulation. Right panel: V β subgroup analysis of flow cytometry-sorted MHC multimer binding T cells (EPL, RAK, and HPV) on day 9 after peptide stimulation. (B) Individual clonotype distribution within CD8⁺ T cells on day 0 and day 9 (left panel) and in multimer-sorted T cells on day 9 (right panel). Each dot represents the frequency (percentage of all sequencing reads) of a single TCR β clonotype. The 25 most frequent clonotypes of each sample are illustrated. (C) Left panel: Overlap of the number of TCR β clonotypes within CD8⁺ T cells on day 0 and day 9. The table shows the presence of the 276 shared TCRs from days 0 and 9 in total CD8⁺ T cells and in EPL-, RAK-, and HPV-sorted CD8⁺ T cells from day 9, along with their cumulative percentage in total CD8⁺ T cells per day. Right panel: Number of epitope-specific TCR β clonotypes and their proportion of cumulative TCR β sequence reads within the overall CD8⁺ T cell product on day 9.

Individual clonotypes were defined as TCR β complementarity-determining regions 3 (CDR3) DNA sequences with a percentage of reads equal to or above the cut-off of 0.01%. We compared the frequencies of the 25 most abundant TCR β clonotypes at day 0 and day 9 of the CD8⁺ T cells, ordered by read frequency in descending order (Fig 2B, left panel). While the percentage of the most common clonotype (labeled by arrow) of the total CD8⁺ T cell fraction on day 0 was 1.4%, the most dominant clonotype on day 9 reached 14.5%.

Analysis of the clonotype distribution of multimer-sorted T cells (Fig 2B, right panel) revealed a steep distribution curve for epitope HPV-sorted T cells with the most dominant single TCR β clonotype (CASGTEAFF) representing 38.8% of all HPV-sorted TCR β sequence reads. In contrast, RAK- and EPL-sorted CD8⁺ T cells showed a less steep distribution curve, indicating a higher variety of different TCR β clonotypes.

A higher percentage of the most common clonotype correlated with a lower total number of different clonotypes per sample. This correlation was also present in clonotype numbers in CD8⁺ T cells before and after peptide stimulation (Fig 2C, left panel). At day 0, we identified 1,957 different TCR β clonotypes (cutoff 0.01% of reads) derived from an equivalent of approximately 14,500 T cells (100 ng

input DNA). This number was reduced to 471 clonotypes after stimulation, and 276 of these were shared in both samples. These 276 clonotypes accounted for 27.4% of total sequence reads on day 0 and for 80.8% of reads on day 9. Of these 276 clonotypes, 209 were found in three groups but with considerable overlap among the groups: EPL (108), RAK (97), and/or HPV (96) peptide-MHC multimer-binding T cell populations. These 209 clonotypes accounted for 19.6% of all CD8⁺ TCR β sequence reads of the healthy donor (day 0). This fraction increased to 92.0% of all detected CD8⁺ T cell TCRs in the peptide-stimulated T cell product (day 9).

After flow cytometric cell sorting with the three peptide-MHC multimers, a total of 327 clonotypes were present in cells sorted with EPL multimer, 313 clonotypes in RAK-sorted cells, and 341 clonotypes in HPV-sorted cells. Due to the overlap of sequences among multimer-sorted populations, we established two additional filters to clearly identify epitope-specific clonotypes: (1) a frequency cutoff of 0.1% before and after multimer sorting, and (2) a requirement that epitope-specific clonotypes were at least ten times more highly enriched in one of the multimer-sorted cultures than in the other two (ternary exclusion criterion). This analysis resulted in the identification of 40 EPL-, 28 RAK-, and 9 HPV-specific TCRs. (Fig 2C, right panel, epitope-specific clonotype identification in S1 Fig, TCR overview in S2-S4 Tables). Notably, the 77 epitope-specific clonotypes represented 74.7% of all TCR β reads on day 9. This finding confirmed that day 9 peptide-expanded T cells were dominated by EBV epitope-specific CD8⁺ T cells. Among these, the 9 HPV-specific clonotypes accounted for 29.5% of all CD8⁺ clonotypes on day 9, which again reflects the steep distribution curve shown in Fig 2B (right panel) and the high proportion of dominant clonotypes such as CASGTEAFF in the HPV-sorted fraction.

To illustrate how EBV peptide-sorted T cell clonotypes expanded after peptide stimulation, the 30 most common TCR β clonotypes on day 0 and day 9 as well as the 10 most common clonotypes of EPL-, RAK-, and HPV-sorted T cells are listed in Table 2. Therein, the most dominant TCR β clonotype for 3 EBV peptides is color-coded according to the peptide. Peptide stimulation resulted in a strong expansion of the dominant clonotypes for the three peptides. The dominant HPV-sorted TCR β clonotype (CASGTEAFF) was also the most dominant one in day 9 CD8⁺ T cells and had been expanded 24-fold as

compared to day 0. Within the multimer-sorted T cell fraction, this specific clonotype accounted for 38.8% of sequencing reads. Similar results were obtained for EPL and RAK dominant clonotypes. However, the HPV-specific TCR β clonotype CASGTEAFF was found three times due to different DNA sequences coding for the identical amino acid sequence. Overall, these three clonotypes accounted for 66.2% within the HPV-sorted fraction.

Table 2. Expansion of distinct clonotypes after EBV-derived peptide stimulation.

CD8 ⁺ T cells day 0		CD8 ⁺ T cells day 9		HLA multimer-sorted T cell product		
reads (%)	CDR3	reads (%)	CDR3	reads (%)	CDR3	peptide
1.426	CASTTPGGRNEKLFF	14.464	CASGTEAFF	13.732	CASRDRVGSEAFF	EPL
1.426	CATSRARGSGANVLTF	10.491	CASSSQRQGRTYEQYF	5.709	CASSDSGTTFNEQFF	
1.271	CSAKGSLETEAFF	7.862	CASSTSRGAGNTIYF	3.672	CASSDSGIHNSPLHF	
1.044	CASSYPGQLNEKLFF	7.020	CASGTEAFF	3.487	CASSDTSALNTEAFF	
0.975	CASSQDPGNTEAFF	2.700	CASGTEAFF	3.425	CAISTGDSNQPQHF	
0.757	CASSEGYSNQPQHF	2.407	CASTSSRGGGNTIYF	3.132	CASRGGQGQETQYF	
0.629	CSASDTGISGANVLTF	2.359	CASGNEQYF	2.604	CASRTGEVNEQFF	
0.605	CASGTEAFF	2.028	CASSQASYVQGDGYTF	2.081	CASSTGDSNQPQHF	
0.572	CASSQDYAGHQPHF	1.959	CASRDRVGSEAFF	1.817	CASGTFDSNQPQHF	
0.454	CSAKGGYDTEAFF	1.929	CASGSEAFF	1.730	CASSDSGMTEAFF	
0.440	CASSLNPEGTYEQYF	1.339	CAISTGDSNQPQHF	38.810	CASGTEAFF	HPV
0.436	CSVRGRENSPLHF	1.170	CASSPGGGTEAFF	17.472	CASGTEAFF	
0.356	CASSMALTATNEKLFF	1.144	CASSSLNTEAFF P2	9.966	CASGTEAFF	
0.354	CASSPTGNTEAFF	0.984	CSARDRGDTYEQYF	7.303	CASGSEAFF	
0.347	CASSTSRGAGNTIYF	0.940	CASRTGEVNEQFF	3.890	CASRPTGFDGYTF	
0.326	CASSQESDYGYTF	0.925	CSAGQGEGYEQYF	1.998	CASGNEQFF	
0.319	CASSQADSFSGNTIYF	0.863	CASRPPGPFYEQYF	1.383	CSAALRPVPRTGYTF	
0.273	CASSQESGHLNTEAFF	0.862	CASSTGVDNQPQHF	1.130	CASSSRSGELFF	
0.246	CASSAETGGGEKAFF	0.853	CASSQGLPLNTEAFF	1.019	CASIPRTKTEAFF	
0.242	CASRDRVGSEAFF	0.827	CASSYGPYEQYF	0.636	CASGNEQFF	
0.226	CASSQGPNYEQYF	0.746	CASSDSGIHNSPLHF	18.947	CASSTSRGAGNTIYF	RAK
0.217	CASSIGQAYEQYF	0.729	CASRGGQGQETQYF	9.985	CASSSQRQGRTYEQYF	
0.216	CASSES PAGEYF	0.672	CASSDSGTTFNEQFF	5.449	CASSQGLPLNTEAFF	
0.203	CSARDPGSSYEQYF	0.583	CASSSLNTEAFF P2	5.294	CASTSSRGGGNTIYF	
0.202	CASSLAPGYLYYEQYF	0.479	CSARGASPQANYGYTF	2.834	CSAGQGEGYEQYF	
0.195	CSARGGETE AFF	0.432	CASSDTSALNTEAFF	2.810	CASSSLNTEAFF P2	
0.192	CASSEAGTGRSEQYF	0.427	CASSYSSFRGGNSPLHF	2.442	CASSSLNTEAFF P2	
0.189	CASSKTMGMGTDQYF	0.414	CASGNEQFF	2.330	CASSLIASGGYNEQFF	
0.186	CASGTEAFF	0.403	CASSSLNTEAFF	2.025	CASSQGVTDYWNEQFF	
0.175	CASSLSYEQYF	0.394	CASSQPGGLEQYF	1.946	CASSQGTGFNYGYTF	

Ranking of the top 30 TCR β clonotypes in donor-derived CD8 $^{+}$ T cells before peptide stimulation (day 0, left column), after peptide stimulation (day 9, middle column), and after peptide stimulation with HLA multimer FACS sorting on day 9 (right column, top 10 clonotypes for each specificity). Clonotypes with identical CDR3 peptide sequence are presented separately in case of a different underlying CDR3 DNA sequence and marked in a red box. The most dominant clonotype per multimer-sorted T cells are color-coded regarding the peptide used for sorting. P2: public clonotypes previously published. [47]

T cell expansion after adoptive T cell transfer

To follow the *in vivo* fate of adoptively transferred peptide-stimulated T cells, we analyzed the peripheral blood of the patient before and after transfer. Fig 3A shows T cell immune reconstitution in absolute T cell numbers after allo-SCT. Between day 34 and day 89, we observed massive expansion of CD4 $^{+}$ cells that was caused by the relapse of the underlying CD4 $^{+}$ AITL, as confirmed on a molecular level by preponderance of a single T-cell clonotype in a lymph node (S2 Fig). This hematologic relapse was accompanied by high fever and EBV reactivation emerging on day 66 and peaking on day 89 with 140,000 copies per ml peripheral blood (Fig 3A). The patient received four Rituximab doses weekly, starting on day 68, and an unseparated donor lymphocyte infusion (DLI) containing 5.0 Mio. CD3 $^{+}$ T cells/kg body weight on day 76 (S1 Table). No further therapy was given at that point. Over the course of the following 21 days, T cell counts and EBV levels strongly decreased. When peripheral blood was analyzed on day 85, 9 days after DLI, by flow cytometry using HLA-specific EBV-derived peptide-MHC multimers, we could not detect T cells binding to HLA-peptide multimers of any of the six known HLA-relevant epitopes listed in Table 1 (data not shown). We therefore decided to generate an EBV-derived peptide-stimulated T cell product from frozen DLI portions. This product was transferred at a dose of 1.0 Mio CD3 $^{+}$ T cells/kg body weight on day 105 post-allo-SCT. As shown in Fig 3A, CD8 $^{+}$ T cells expanded after adoptive transfer for 8 days (day 105 to 113), followed by a decline over 13 days until day 126 and stable maintenance thereafter.

Fig 3. T cell and clonotype expansion after allogeneic stem cell transplantation and adoptive transfer of EBV-specific T cells.

(A) Flow cytometric monitoring of absolute numbers of CD4⁺ and CD8⁺ T cells and EBV DNA copy number in peripheral blood. Relapse of the CD4⁺ T cell lymphoma was detected on day 56 in peripheral blood. Time points of Rituximab application are marked with an asterisk (*). ATCT= adoptive T cell transfer. (B) TCR clonotype diversity in CD4⁺ and CD8⁺ T cells in peripheral blood of the patient. For comparison, the diversity in donor's PBMC is shown. (C) Flow cytometric monitoring of peripheral blood CD8⁺ T cells using HLA peptide-MHC multimers (EPL, RAK, HPV) on the day of ATCT (day 105) and thereafter. (D) Cumulative frequency of TCR clonotypes specific for each of the epitopes EPL, RAK, and HPV in CD8⁺ T cell populations. Data points for donor's PBMC, T cell product after peptide stimulation, and peripheral blood of the patient before (day 60) and after ATCT (day 120, day 180, and day 230) are shown.

When the TCR β repertoire within the donor's PBMC fraction used as DLI (Fig 3B, day 0) was analyzed, we obtained 2375 clonotypes within the CD4⁺ compartment and 1957 clonotypes within the CD8⁺ compartment, which is a typical degree of TCR diversity observed in healthy donors with the assay used here [46]. Consistent with an expected narrowing of the TCR repertoire following allo-SCT [48], our patient's TCR β repertoire was strongly reduced in both compartments (CD4⁺: 236, CD8⁺: 108 clonotypes) on day 60 after allo-SCT (before DLI and adoptive transfer of EBV peptide-stimulated T cells). In line with hematologic relapse, one clone was predominant in the CD4⁺ fraction of peripheral blood (CSARDRTGSEKLFF). This clone represented the CD4⁺ AITL, which was confirmed by analysis of DNA retrieved from a lymph node biopsy at the time of initial diagnosis (S2 Fig). On day 120 (fifteen days after adoptive transfer of peptide-stimulated T cells), we observed an increase in T cell diversity, which was higher in CD8⁺ T cells (645 clonotypes) than in CD4⁺ T cells (402 clonotypes). This suggested that adoptive transfer on day 105 contributed to diversification of the patient's TCR repertoire, in particular through transfer of EBV-specific CD8⁺ T cells.

Multimer staining was used to track EBV-specific T cells until day 232 after allo-SCT (Fig 3C). We observed a strong expansion of EPL- and RAK-specific CD8⁺ T cells, which were two of the three dominant EBV specificities in the T cell product. On day 105, immediately before adoptive transfer, a

small fraction of HLA multimer-binding CD8⁺ T cells had been detectable in peripheral blood. Over the course of 8 days after transfer, RAK- and EPL-multimer-binding CD8⁺ T cells strongly expanded *in vivo* (from 14/μl to 55/μl and from 28/μl to 120/μl, respectively). Analysis of the TCRβ repertoire (Fig 3D) before adoptive T cell transfer (ATCT) on day 60 revealed that the patient had not mounted a significant T cell response against EPL, RAK, and HPV epitopes: Only 6 of 77 epitope-specific clonotypes were detectable. This situation had changed 15 days after adoptive transfer of peptide-stimulated T cells (day 120), when the total number of different multimer-binding clonotypes present had increased to 61. In comparison to day 60, by day 120 EPL- and HPV-specific T cell read frequencies increased significantly (EPL: from 3.67% to 15.43%, HPV: 0.00% to 2.37%), while RAK was relatively stable (RAK: 4.78% to 5.06%). Thereafter, clonotype diversity in CD8⁺ T cells remained rather constant (Fig 3B), while epitope-specific clonotypes gradually declined until day 232 but were detectable throughout the observation period (follow-up of epitope-specific TCRs in S5 Table).

A complete frequency analysis of the 77 EBV epitope-specific clonotypes is shown in Fig 4A as a heat map (comparison in the T cell product before and after multimer sort in S3 Fig). At the beginning of the EBV peptide-stimulated T cell product manufacture (which at this point represents the donor's natural T cell repertoire on day 0), we found 55 EBV-specific clonotypes to be present in the patient at this time. These clonotypes represent 5.43% of the CD8⁺ TCRβ repertoire before peptide-stimulation on day 0 (S5 Table). 15 days after adoptive transfer (day 120), the 77 EBV epitope-specific clonotypes accounted for 22.86% of all TCR gene reads found in the patient. On our last measurement (day 232), 45 EBV-specific clonotypes remained detectable, representing 8.49% of all TCR reads. Thus, by adoptive transfer of peptide-stimulated T cells, we reinstalled a large part of the donor's specific T cell repertoire targeting three EBV epitopes, which is especially reflected by the dominant clonotypes for each epitope (Fig 4B upper panel and Table 2). EBV-specific T cell reconstitution in the patient included two previously described (and thus public) clonotypes specific for EPL and RAK (Fig 4B, lower panel, and Table 2), but one of these became undetectable on day 232 [31, 33]. It is noteworthy that neither

296 dominant nor proven public clonotypes were found among the 6 EBV-specific clonotypes on day 60 in
297 the patient, when EBV began to reactivate in the period before ATCT.

298 **Fig 4. Frequencies of specific TCR β clonotypes before and after adoptive T cell transfer.**

299 (A) Frequency heatmap of individual epitope-specific TCR clonotypes in donor PBMC, T cell product,
300 and four time points after transplantation in the patient (day 60, day 120, day 180, and day 232).
301 Clonotype frequency is displayed as a percentage from 0.01% (limit of detection) to 14.4637 by
302 increasing colour depth. Each row represents one specific TCR clonotype. Identified public TCR
303 sequences (P1 and P2) previously published [47, 49] are shown in grey boxes. The most dominant
304 clones (D1-3) within each specificity are shown in pink boxes. ATCT: adoptive T cell transfer. (B)
305 Frequencies of public clonotypes (P) and dominant clonotypes (D) in different samples.

Discussion

Adoptive transfer of EBV-specific T cells for the treatment of EBV-associated lymphoma in the immunocompromised host has been shown to effectively mediate virus control [50]. Furthermore, it has been demonstrated that adoptively transferred EBV-specific T cells contribute to long-term immunity [20]. However, although several dominant EBV-derived T cell epitopes and their HLA restriction were identified over the past decades [30–43], it remains unclear which and how many TCRs recognize those epitopes and are being expanded *in vivo*. Follow-up in patients after primary infection with EBV suggests few clonotypes with high frequencies dominate epitope-specific responses long-term [51]. Similar observations were made after adoptive transfer of EBV-specific T cells [52, 53], thus pointing towards TCR clonotypes of potential clinical interest. Beyond single clonotypes, EBV-specific T cell frequencies, repertoire diversity, and long-term survival of TCR clonotypes contribute to control active EBV infection [54], latency [55], and EBV-associated malignancies [56–58].

In this study, we extensively analyzed the fate of adoptively transferred T cells enriched for specificity against EBV-derived epitopes by flow cytometry and high-throughput sequencing of TCR β rearrangements. We demonstrated that *in vitro* stimulation of PBMC with defined peptides results in strong expansion of EBV epitope-specific CD8⁺ T cells. Furthermore, we showed by TCR β high throughput sequencing that adoptive transfer of peptide-stimulated T cells to a patient results in the establishment and maintenance of a diverse EBV-specific T cell repertoire.

This study was carried out on an EBV-seropositive patient who, after chemotherapy and allo-SCT to treat a CD4⁺ AITL, suffered from relapse and simultaneous increase of EBV load, probably connected to reemergence of malignancy. High EBV viremia is associated with AITL progression, which suggests a possible role in its pathogenesis [2] and increased aggressiveness [4]. Despite DLI and Rituximab treatment, adoptive transfer of T cells enriched for EBV epitopes was provided due to increasing levels of EBV viral DNA in blood and lack of EBV peptide-MHC multimer-binding T cells for six known HLA-relevant epitopes. Owing to the risk of recurrent EBV reactivation [59] and its association with AITL

pathogenesis and histological development, we believe adoptive transfer of EBV-specific T cell products hold promise for the treatment of AITL [60, 61].

By monitoring the TCR β sequences identified as EBV epitope-specific at different time points, we demonstrated that T cell clonotypes enriched in the T cell product persist long term in the patient. From this study, we conclude that *in vitro* T cell stimulation with a defined set of peptides results in broad but specific TCR β repertoire expansion of various dominant clonotypes for relevant epitope specificities. They might therefore contribute to reinstallation of a natural occurring immunity similar to the one observed in the donor.

Our TCR high-throughput sequencing approach is based on samples of 100 ng cellular DNA and therefore has a limited resolution of 14,500 T cells, with a frequency cut-off of 0.01% (approximately 100 reads per T cell). This is suitable to obtain insights into clonotype diversity but will not detect every virus-specific TCR clonotype in patient samples or T cell products. High-throughput sequencing was able to reveal multiple EBV-specific clonotypes even in the complex T cell repertoire of the healthy donor, whose cells were used to manufacture EBV-specific T cells for adoptive transfer.

Expansion of EPL-, RAK-, and HPV-MHC multimer-binding T cells after peptide stimulation correlated with the expansion of distinct clonotypes, as shown by flow cytometry and TCR β high throughput sequencing. However, we found TCRs in the MHC multimer-sorted CD8⁺ population that were not enriched (as compared with unsorted populations) but were still detectable, presumably due to unspecific MHC multimer-binding. Nonetheless, this fraction represented the purest pool of T cells for a defined specificity and was used to for multimer ternary exclusion.

We mapped TCR sequences from peptide-MHC multimer-binding T cells back to the unsorted T cell pools before (d0) and after (d9) peptide stimulation. Using this strategy, we were able to identify previously described TCR β sequences [31, 32] and numerous new and naturally occurring clonotypes with relatively high frequencies in the normal donor. For example, three sequences with three distinct specificities found in the donor (Table 2, highlighted) accounted for 1.1% of the donor's repertoire. These were among the donor's 30 clonotypes with the highest frequencies and persisted long term

after adoptive transfer in the patient. The presence of dominant clonotypes for single peptide specificities is reinforced by the fact that three different DNA sequences coded for HPV-specific TCR β clonotype CASGTEAFF.

TCR clonotypes complying with both inclusion criteria (frequency above 0.1% before and after multimer sort in T cell product and multimer ternary analysis) were identified as EBV epitope-specific. The frequency cutoff of 0.1% was selected to reduce noise, while ternary analysis allows us to exclude unspecific multimer-binding clonotypes. Using both criteria combined, we were able to identify EBV epitope-specific T cells which clearly dominate the T cell product (77 of 471 clonotypes account for 74.8% of reads) and persist long-term after adoptive transfer.

It is relevant that such few EBV-specific clonotypes were detectable on day 60, while the patient's EBV viral load in peripheral blood was increasing. In contrast, EBV epitope-specific clonotypes from the unsorted and MHC multimer-sorted CD8⁺ populations on day 9 were found 15 days after adoptive transfer (day 120) with a significant increase in frequencies and diversity of TCR clonotypes (Fig 4A). Therefore, we could see an association between the presence of several EBV epitope-specific clonotypes on day 120 and the absence of EBV DNA in the peripheral blood thereafter. Due to the association of EBV infection and AITL relapse, EBV control could have positively influenced AITL regression, as has been observed in PTLD [62].

Success of ATCT after allo-SCT depends on restoring immunity against viruses without viral reactivation, in the absence of Graft versus Host Disease (GvHD) [63]. Several indicators of restored EBV-specific T cell immunity are: (i) the persistence of adoptively transferred, functional virus-specific T cells [20, 64–66], (ii) absence and regression of EBV-associated lymphomas [62, 67–69], and (iii) control of virus reactivation and viremia *in vivo* [66, 70–73]. We would therefore argue that the presence of EBV epitope-specific, expanded clonotypes in the T cell product, their long-term persistence in the patient, and lack of further EBV reactivation or relapse point to an important role of these clonotypes in controlling EBV, AITL, and other EBV-associated malignancies.

383 In conclusion, we were able to confirm the long-term presence of expanded, EBV epitope-specific CD8⁺
 384 T cell clonotypes following adoptive transfer in the patient, thereby restoring anti-EBV T cell immunity.
 385 To further validate these findings, a recently closed multicenter phase I/IIa clinical study
 386 (NCT02227641, EudraCT: 2012-004240-30) used this manufacture technique to generate T cell
 387 products with double specificity against CMV and EBV for patients after allo-SCT. The results of this
 388 study will further increase our knowledge on potentially protective virus-specific TCR repertoires after
 389 allo-SCT.

Material and Methods

Patient history

An overview of the patient history is provided in S1 Table. The 55-year-old, EBV-seropositive patient suffered from chemotherapy-refractory AILT (Stage IVB), which was confirmed by a lymph node biopsy (S2 Fig), and was transplanted with G-CSF-mobilized peripheral blood stem cells from an HLA 10/10 matched unrelated donor. The patient relapsed shortly after transplantation (day 42) and received conventional unmanipulated DLI (day 76) and subsequently, due to EBV reactivation, peptide-stimulated EBV-specific T cells (day 105).

Ethics, informed consent

The patient gave written informed consent prior to transplantation for extended immunomonitoring using standard flow cytometry, multimer analysis, and TCR HTS. The ethics committee of Friedrich-Alexander-University Erlangen-Nürnberg gave approval for this study (approval No.: 4388). In addition, the patient gave written consent for the attempt to cure using donor-derived EBV-specific T cells.

Generation of EBV-specific T cells

EBV-specific peptides were generated in a GMP-conform fashion as described previously [65]. Peptides used for stimulation are shown in Table 1. In brief: frozen donor lymphocytes were obtained and thawed for Ficoll density centrifugation, yielding 826×10^6 PBMC. PBMC were frozen until use. 600 million PBMC were incubated with peptide mix for 2h. After subsequent washing steps, cells were incubated in a closed bag system for 9 days. Medium was added according to the manufacturing protocol on day 5. Quality assessment of the product included bacterial culture and eubacterial PCR, flow cytometric analysis, and trypan blue method for viability.

Flow cytometry analysis of cultivated cells and peripheral blood

To quantify cell types, peripheral blood (50 µl per sample) was stained in TruCount tubes containing fluorescent beads (BD Biosciences) with the following antibodies: anti-CD8 FITC (clone SK1), anti-CD25

414 PE (clone 2A3), anti-CD14 PerCP (clone MφP9), anti-CD56 APC (clone B159), anti-CD19 PE-Cy7 (clone
415 SJ25C1), anti-CD4 APC-Cy7 (clone RPA-T4), anti-CD3 V450 (clone UCHT1), and anti-CD45 V500 (clone
416 HI30, all clones from BD Bioscience). After incubation at room temperature for 15 min, 450 µl of red
417 cell lysis buffer (BD Biosciences) was added and samples were incubated for further 20 min. Cells were
418 analyzed subsequently after staining using a FACS Canto II flow cytometer (Becton Dickinson).
419 Leukocytes were gated as CD45⁺ and lymphocytes as CD45^{high}CD14⁻ cells. Within the lymphocyte
420 population, T cells were determined as CD3⁺, B cells as CD19⁺, NK cells as CD56⁺ cell populations. T cell
421 subpopulations were analyzed for CD4 and CD8 expression. Cell counts/µl were calculated based on
422 bead count and sample volume in TruCount tubes (BD Bioscience). Cultivated cells were stained with
423 the same panel but without cell quantification by TruCount tubes.

424 For analysis of T cells with multimer staining, 1x10⁶ cells either PBMC isolated from peripheral blood
425 by Ficoll density centrifugation or taken from cultivated cells on day 0 and day 9, were stained with
426 HLA-matched peptide-MHC pentamers (ProImmune, Oxford, UK), and subsequently counterstained
427 with PE-fluorotag (Proimmune), anti-CCR7 FITC (clone 150503, R&D Systems, Minneapolis, MN, USA),
428 anti-CD8 PerCP (clone SK1), anti-CD62L APC (clone DREG-56), anti-CD45RA PE-Cy7 (clone HI100), anti-
429 CD4 APC-Cy7 (clone RPA-T4), and anti-CD3 V450 (clone UCHT1, all clones BD Biosciences). Cells were
430 analyzed using a FACS Canto II flow cytometry analyzer (Becton Dickinson). Vital lymphocytes were
431 gated in FSC vs. SSC. T cells were identified by their CD3 expression. T cell subpopulations were
432 identified by CD4 and CD8 expression. T cells binding an EBV peptide-MHC multimer were analyzed
433 within the CD8⁺ T cell population.

434 Cultivated cells after harvest were further analyzed for IFN-γ production upon antigen-specific
435 restimulation. Therefore, day 9 cells were restimulated with the epitopes RLR, RAK, QAK, EPL, HPV, or
436 YPL (each peptide 0.5µg/ml), or PMA-ionomycin for positive control. To inhibit IFN-γ secretion,
437 GolgiStop (BD Biosciences) was added for the time of restimulation (5 hours). Afterwards, cells were
438 harvested and stained with the following surface markers: anti-CD3 PerCP (clone SK7), anti-CD8 PE-
439 Cy7 (SK1), and anti-CD4 APC-Cy7 (clone RPA-T4). Then, cells were washed and treated with 250µl

CellFix /Perm buffer (BD Biosciences) for 20 minutes, 4°C. Cells were then washed with Perm-/Wash buffer (BD Biosciences) and subsequently intracellularly stained with anti-IFN- γ -FITC (clone B27) for 30 minutes at 4°C. Afterwards, cells were once washed with Perm-/Wash-buffer and once with PBS. After cell fixation, samples could be analyzed by flow cytometry.

Cell sorting

Whole blood samples (EDTA) were processed by density gradient centrifugation (Ficoll) to obtain mononuclear blood cells (PBMC). For flow cytometry sorting, PBMC were stained with anti-CD4 FITC (clone SK3), anti-CD8 PE (clone SK1), anti-CD14 PerCP (clone M ϕ P9, all clones BD Biosciences, Franklin Lakes, NJ, USA), and anti-TCR $\alpha\beta$ (clone BW242/412, Miltenyi Biotec, Bergisch Gladbach, Germany). Cells were gated on (i) vital lymphocytes in forward/side scatter, (ii) exclusion of doublets, and (iii) TCR $\alpha\beta$ ⁺ CD14⁻ T cells. Within the T cell population, CD4⁺ and CD8⁺ T cells were sorted into separate tubes (MoFlow, Beckman Coulter, Brea, CA, USA). A purity of > 98.0% was achieved as monitored by reanalysis of the sorted samples.

Multimer cell sorting was performed using HLA-matched peptide-MHC pentamers obtained from ProImmune. Of the EBV-specific expanded T cells (day 9), 40x10⁶ cells were incubated with RAK-HLA-B*08:01-, 40x10⁶ cells with HPV-HLA*B35:01-, and 18x10⁶ cells with EPL-HLA*B35:01-multimers, according to manufacturer's recommendation. Afterwards cells were washed and stained with PE-fluorotag (ProImmune) binding to the peptide loaded HLA multimers, anti-CD8 FITC (clone SK1, BD Biosciences), anti-CD14 PerCP (clone M ϕ P9, BD Biosciences), and anti-TCR $\alpha\beta$ (clone BW242/412, Miltenyi Biotec, Bergisch Gladbach, Germany). Cells were gated on (i) vital lymphocytes in forward/side scatter, (ii) exclusion of doublets, and (iii) TCR $\alpha\beta$ ⁺ CD14⁻ T cells. Then, the CD8⁺ multimer-binding population was sorted out and used for further analysis by TCR β sequencing.

DNA isolation

DNA was extracted from flow cytometry-sorted T cells using the Qiagen AllPrep DNA/RNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Quantification of the extracted DNA was done employing a Qubit® 1.0 Fluorometer (Invitrogen, Carlsbad, CA, USA).

Capillary electrophoresis

CDR3 length repertoires of TCR β sequences were generated by using the BIOMED-2 primer sets for PCR-based clonality analysis [74]. The fluorescence-labeled amplicons were size-separated and detected via automated laser scanning by a 3130 Genetic Analyzer (Applied Biosystems; Darmstadt, Germany).

High-throughput sequencing of TCR β gene clonotypes

Amplification of TCR β from 100 ng of cellular DNA (approximately 14,500 T cells) with multiplex PCR, sequencing of amplified TCR β gene libraries (HiSeq2000), and data processing were performed as previously described [46]. Employing a two-step PCR strategy, the TCR β amplicons were tagged with universal Illumina adapter sequences, including an additional barcode during a second amplification step, allowing parallel sequencing of several samples on Illumina HiSeq2000 (Illumina, San Diego, CA). Our amplicon sequences covered the entire CDR3 length and V β and J β segments in parts and using the Illumina paired-end technology (2x 100 bp) provided a high sequence accuracy.

The multiplex primers used contain a universal adapter sequence as a tail at the 5' end complementary to the 3' ends of second amplification adaptor primers. The adaptor PCR primers contained universal sequences that permitted solid-phase PCR on the Illumina Genome Analyzer (HiSeq 2000 Sequencing System). Primary amplification (final volume: 50 μ L) was processed, including 100 ng DNA, 1.0 μ M equimolar V β and J β primer pools, PCR buffer, 3mM MgCl₂, 0.2mM of each dNTP and 1U AmpliTaq Gold DNA Polymerase (Applied Biosystems, Foster City, CA). The amplification was performed on a DNA thermal cycler (GeneAmp1 PCR System 9700, Applied Biosystems) for 34 cycles at 62°C annealing temperature. All PCR products were purified using the QIAquick PCR Purification Kit (Qiagen) and diluted (final amount: 500 pg) for further amplifications. Adapter PCRs were set up with Phusion HF

Buffer, 1.0 μ M forward and reverse adapter primers, 0.05mM of each dNTP and 1U Phusion High-Fidelity DNA Polymerase (Finnzymes, Espoo, Finland). Secondary amplification was performed for 12 cycles at 58°C annealing temperature. Products were isolated from a 2% agarose gel using the Wizard1 SV Gel and PCR Clean-Up System (Promega, Mannheim, Germany). DNA concentration was determined via the Qubit1 1.0 Fluorometer (Invitrogen) [46]. Clonotypes were defined as TCR β clonotypes with a percentage of reads equal to or above a 0.01% cut-off. Reads with frameshift or stop codon were considered as non-functional TCR β rearrangements and excluded from analysis.

Peptides

The manufacturing process involved stimulation of peripheral mononuclear cells by a fixed pool of peptides derived from various EBV proteins. The sequence of selected peptides, their HLA restriction, and reference is shown in Table 1. Peptides were synthesized by JPT Peptides Berlin (Germany) at a purity of 95%. All raw materials used for peptide synthesis were CE certified and all materials were fully synthetic. 5% contamination of the peptide product is considered to be smaller oligomers of the original design, due to inefficient elongation.

Identification of EBV epitope-specific TCR clonotypes

We applied two criteria to TCR clonotypes found in the T cell product, either before or after multimer sort, to consider them as epitope-specific: First, we used a cutoff of 0.1%, representing approximately 10 T cells, to reduce noise. Then, we applied a ternary exclusion criterion based on the multimer enrichment ratio, defined as frequency after multimer sort / frequency before multimer sort. The enrichment factor for a given multimer must be at least ten times bigger than for the other two multimers to be considered epitope-specific.

Acknowledgements

We would like to thank the staff of the department for transfusion medicine for their kind support of this study. Many thanks go to the staff of the Erlangen Bone Marrow Transplantation (BMT) unit and BMT outpatient clinic for excellent care taking of the patient.

References

- [1] Ru Y, Zhang X, Song T, *et al.* Epstein-Barr virus reactivation after allogeneic hematopoietic stem cell transplantation: multifactorial impact on transplant outcomes. *Bone Marrow Transplant* 2020; 55(9): 1754–62
[<https://doi.org/10.1038/s41409-020-0831-7>][PMID: 32066862]
- [2] Zhou Y, Attygalle AD, Chuang S-S, *et al.* Angioimmunoblastic T-cell lymphoma: histological progression associates with EBV and HHV6B viral load. *Br J Haematol* 2007; 138(1): 44–53
[<https://doi.org/10.1111/j.1365-2141.2007.06620.x>][PMID: 17555446]
- [3] Wang C, Gong Y, Liang X, Chen R. Epstein–Barr Virus Positive Diffuse Large B-Cell Lymphoma Transformed Into Angioimmunoblastic T-Cell Lymphoma After Treatment: A Case Report and Literature Review 2021.
- [4] Facchinelli D, Polino A, Dima F, Parisi A, Ambrosetti A, Veneri D. Two cases of angioimmunoblastic T-cell lymphoma with concomitant positive serology for acute Epstein-Barr virus infection. *Hematol Rep* 2017; 9(3): 7088
[<https://doi.org/10.4081/hr.2017.7088>][PMID: 29071053]
- [5] Weiss LM, Jaffe ES, Liu XF, Chen YY, Shibata D, Medeiros LJ. Detection and localization of Epstein-Barr viral genomes in angioimmunoblastic lymphadenopathy and angioimmunoblastic lymphadenopathy-like lymphoma. *Blood* 1992; 79(7): 1789–95
[PMID: 1373088]
- [6] Kishimoto W, Takiuchi Y, Nakae Y, *et al.* A case of AITL complicated by EBV-positive B cell and monoclonal plasma cell proliferation and effectively treated with lenalidomide. *Int J Hematol* 2019; 109(4): 499–504
[<https://doi.org/10.1007/s12185-018-02587-6>][PMID: 30604313]
- [7] Takahashi T, Maruyama R, Mishima S, *et al.* Small bowel perforation caused by Epstein-Barr virus-associated B cell lymphoma in a patient with angioimmunoblastic T-cell lymphoma. *J Clin Exp Hematop* 2010; 50(1): 59–63
[<https://doi.org/10.3960/jslrt.50.59>][PMID: 20505277]
- [8] Anagnostopoulos I, Hummel M, Finn T, *et al.* Heterogeneous Epstein-Barr virus infection patterns in peripheral T- cell lymphoma of angioimmunoblastic lymphadenopathy type. *Blood* 1992; 80(7): 1804–12
[<https://doi.org/10.1182/blood.V80.7.1804.1804>]
- [9] Lee WJ, Won KH, Choi JW, *et al.* Cutaneous angioimmunoblastic T-cell lymphoma: Epstein-Barr virus positivity and its effects on clinicopathologic features. *J Am Acad Dermatol* 2019; 81(4): 989–97
[<https://doi.org/10.1016/j.jaad.2018.08.053>][PMID: 30240776]
- [10] Battegay M, Berger C, Rochlitz C, *et al.* Epstein-Barr virus load correlating with clinical manifestation and treatment response in a patient with angioimmunoblastic T-cell lymphoma.

- Antivir Ther 2004; 9(3): 453–9
[PMID: 15259909]
- [11] Eladl AE, Shimada K, Suzuki Y, *et al.* EBV status has prognostic implication among young patients with angioimmunoblastic T-cell lymphoma. *Cancer Med* 2020; 9(2): 678–88
[https://doi.org/10.1002/cam4.2742][PMID: 31793218]
- [12] Styczynski J, van der Velden W, Fox CP, *et al.* Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines. *Haematologica* 2016; 101(7): 803–11
[https://doi.org/10.3324/haematol.2016.144428][PMID: 27365460]
- [13] Sanz J, Andreu R. Epstein-Barr virus-associated posttransplant lymphoproliferative disorder after allogeneic stem cell transplantation. *Curr Opin Oncol* 2014; 26(6): 677–83
[https://doi.org/10.1097/CCO.000000000000119][PMID: 25162331]
- [14] Liu L, Liu Q, Feng S. Management of Epstein-Barr virus-related post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation. *Ther Adv Hematol* 2020; 11: 2040620720910964
[https://doi.org/10.1177/2040620720910964][PMID: 32523657]
- [15] Al Hamed R, Bazarbachi AH, Mohty M. Epstein-Barr virus-related post-transplant lymphoproliferative disease (EBV-PTLD) in the setting of allogeneic stem cell transplantation: a comprehensive review from pathogenesis to forthcoming treatment modalities. *Bone Marrow Transplant* 2020; 55(1): 25–39
[https://doi.org/10.1038/s41409-019-0548-7][PMID: 31089285]
- [16] Andrei G, Trompet E, Snoeck R. Novel Therapeutics for Epstein-Barr Virus. *Molecules* 2019; 24(5)
[https://doi.org/10.3390/molecules24050997][PMID: 30871092]
- [17] van der Velden WJFM, Mori T, Stevens WBC, *et al.* Reduced PTLD-related mortality in patients experiencing EBV infection following allo-SCT after the introduction of a protocol incorporating pre-emptive rituximab. *Bone Marrow Transplant* 2013; 48(11): 1465–71
[https://doi.org/10.1038/bmt.2013.84][PMID: 23749107]
- [18] Abdel-Azim H, Elshoury A, Mahadeo KM, Parkman R, Kapoor N. Humoral Immune Reconstitution Kinetics after Allogeneic Hematopoietic Stem Cell Transplantation in Children: A Maturation Block of IgM Memory B Cells May Lead to Impaired Antibody Immune Reconstitution. *Biol Blood Marrow Transplant* 2017; 23(9): 1437–46
[https://doi.org/10.1016/j.bbmt.2017.05.005][PMID: 28495643]
- [19] D'Orsogna LJ, Wright MP, Krueger RG, *et al.* Allogeneic hematopoietic stem cell transplantation recipients have defects of both switched and igm memory B cells. *Biol Blood Marrow Transplant* 2009; 15(7): 795–803
[https://doi.org/10.1016/j.bbmt.2008.11.024][PMID: 19539210]
- [20] Heslop HE, Slobod KS, Pule MA, *et al.* Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. *Blood* 2010;

- 589 115(5): 925–35
590 [<https://doi.org/10.1182/blood-2009-08-239186>][PMID: 19880495]
- 591 [21] Prockop S, Doubrovina E, Suser S, *et al.* Off-the-shelf EBV-specific T cell immunotherapy for
592 rituximab-refractory EBV-associated lymphoma following transplantation. *J Clin Invest* 2020;
593 130(2): 733–47
594 [<https://doi.org/10.1172/JCI121127>][PMID: 31689242]
- 595 [22] Ricciardelli I, Blundell MP, Brewin J, Thrasher A, Pule M, Amrolia PJ. Towards gene therapy for
596 EBV-associated posttransplant lymphoma with genetically modified EBV-specific cytotoxic T
597 cells. *Blood* 2014; 124(16): 2514–22
598 [<https://doi.org/10.1182/blood-2014-01-553362>][PMID: 25185261]
- 599 [23] Bollard CM, Rooney CM, Heslop HE. T-cell therapy in the treatment of post-transplant
600 lymphoproliferative disease. *Nat Rev Clin Oncol* 2012; 9(9): 510–9
601 [<https://doi.org/10.1038/nrclinonc.2012.111>][PMID: 22801669]
- 602 [24] Gary R, Aigner M, Moi S, *et al.* Clinical-grade generation of peptide-stimulated CMV/EBV-specific
603 T cells from G-CSF mobilized stem cell grafts. *J Transl Med* 2018; 16(1): 124
604 [<https://doi.org/10.1186/s12967-018-1498-3>][PMID: 29743075]
- 605 [25] Schaft N, Lankiewicz B, Drexhage J, *et al.* T cell re-targeting to EBV antigens following TCR gene
606 transfer: CD28-containing receptors mediate enhanced antigen-specific IFNgamma production.
607 *Int Immunol* 2006; 18(4): 591–601
608 [<https://doi.org/10.1093/intimm/dxh401>][PMID: 16507598]
- 609 [26] Cho H-I, Kim U-H, Shin A-R, *et al.* A novel Epstein-Barr virus-latent membrane protein-1-specific
610 T-cell receptor for TCR gene therapy. *Br J Cancer* 2018; 118(4): 534–45
611 [<https://doi.org/10.1038/bjc.2017.475>][PMID: 29360818]
- 612 [27] Zhang C, Tan Q, Li S, *et al.* Induction of EBV latent membrane protein-2A (LMP2A)-specific T cells
613 and construction of individualized TCR-engineered T cells for EBV-associated malignancies. *J*
614 *Immunother Cancer* 2021; 9(7)
615 [<https://doi.org/10.1136/jitc-2021-002516>][PMID: 34210819]
- 616 [28] Dudanec K, Westendorf K, Nössner E, Uckert W. Generation of Epstein-Barr Virus Antigen-
617 Specific T Cell Receptors Recognizing Immunodominant Epitopes of LMP1, LMP2A, and EBNA3C
618 for Immunotherapy. *Hum Gene Ther* 2021; 32(17-18): 919–35
619 [<https://doi.org/10.1089/hum.2020.283>][PMID: 33798008]
- 620 [29] Chen L, Dong L, Ma Y, *et al.* An efficient method to identify virus-specific TCRs for TCR-T cell
621 immunotherapy against virus-associated malignancies. *BMC Immunol* 2021; 22(1): 65
622 [<https://doi.org/10.1186/s12865-021-00455-3>][PMID: 34583647]
- 623 [30] Lee SP, Thomas WA, Murray RJ, *et al.* HLA A2.1-restricted cytotoxic T cells recognizing a range of
624 Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2. *J Virol*
625 1993; 67(12): 7428–35
626 [<https://doi.org/10.1128/JVI.67.12.7428-7435.1993>][PMID: 7693972]

- [31] Steven NM, Annels NE, Kumar A, Leese AM, Kurilla MG, Rickinson AB. Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response. *J Exp Med* 1997; 185(9): 1605–17
[<https://doi.org/10.1084/jem.185.9.1605>][PMID: 9151898]
- [32] Scotet E, David-Ameline J, Peyrat MA, *et al.* T cell response to Epstein-Barr virus transactivators in chronic rheumatoid arthritis. *J Exp Med* 1996; 184(5): 1791–800
[<https://doi.org/10.1084/jem.184.5.1791>][PMID: 8920867]
- [33] Saulquin X, Ibsch C, Peyrat M-A, *et al.* A global appraisal of immunodominant CD8 T cell responses to Epstein-Barr virus and cytomegalovirus by bulk screening. *Eur. J. Immunol.* 2000; 30(9): 2531–9
[[https://doi.org/10.1002/1521-4141\(200009\)30:9<2531::AID-IMMU2531>3.0.CO;2-O](https://doi.org/10.1002/1521-4141(200009)30:9<2531::AID-IMMU2531>3.0.CO;2-O)]
- [34] Meij P, Leen A, Rickinson AB, *et al.* Identification and prevalence of CD8(+) T-cell responses directed against Epstein-Barr virus-encoded latent membrane protein 1 and latent membrane protein 2. *Int J Cancer* 2002; 99(1): 93–9
[<https://doi.org/10.1002/ijc.10309>][PMID: 11948498]
- [35] Hill AB, Lee SP, Haurum JS, *et al.* Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised. *J Exp Med* 1995; 181(6): 2221–8
[<https://doi.org/10.1084/jem.181.6.2221>][PMID: 7539044]
- [36] Burrows SR, Gardner J, Khanna R, *et al.* Five new cytotoxic T cell epitopes identified within Epstein-Barr virus nuclear antigen 3. *J Gen Virol* 1994; 75 (Pt 9): 2489–93
[<https://doi.org/10.1099/0022-1317-75-9-2489>][PMID: 7521394]
- [37] Bogedain C, Wolf H, Modrow S, Stuber G, Jilg W. Specific cytotoxic T lymphocytes recognize the immediate-early transactivator Zta of Epstein-Barr virus. *J Virol* 1995; 69(8): 4872–9
[PMID: 7609055]
- [38] Rickinson AB, Moss DJ. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. *Annu Rev Immunol* 1997; 15: 405–31
[<https://doi.org/10.1146/annurev.immunol.15.1.405>][PMID: 9143694]
- [39] Landais E, Saulquin X, Scotet E, *et al.* Direct killing of Epstein-Barr virus (EBV)-infected B cells by CD4 T cells directed against the EBV lytic protein BHRF1. *Blood* 2004; 103(4): 1408–16
[<https://doi.org/10.1182/blood-2003-03-0930>][PMID: 14563644]
- [40] Leen A, Meij P, Redchenko I, *et al.* Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses. *J Virol* 2001; 75(18): 8649–59
[<https://doi.org/10.1128/JVI.75.18.8649-8659.2001>][PMID: 11507210]
- [41] Adhikary D, Behrends U, Moosmann A, Witter K, Bornkamm GW, Mautner J. Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins. *J Exp Med* 2006; 203(4): 995–1006
[<https://doi.org/10.1084/jem.20051287>][PMID: 16549597]

- [42] Mautner J, Pich D, Nimmerjahn F, *et al.* Epstein-Barr virus nuclear antigen 1 evades direct immune recognition by CD4+ T helper cells. *Eur J Immunol* 2004; 34(9): 2500–9
[<https://doi.org/10.1002/eji.200324794>][PMID: 15307182]
- [43] Milosevic S, Behrends U, Adhikary D, Mautner J. Identification of major histocompatibility complex class II-restricted antigens and epitopes of the Epstein-Barr virus by a novel bacterial expression cloning approach. *J Virol* 2006; 80(21): 10357–64
[<https://doi.org/10.1128/JVI.01193-06>][PMID: 17041216]
- [44] Tan LC, Gudgeon N, Annels NE, *et al.* A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers. *J Immunol* 1999; 162(3): 1827–35
[PMID: 9973448]
- [45] Omiya R, Buteau C, Kobayashi H, Paya CV, Celis E. Inhibition of EBV-induced lymphoproliferation by CD4(+) T cells specific for an MHC class II promiscuous epitope. *J Immunol* 2002; 169(4): 2172–9
[<https://doi.org/10.4049/jimmunol.169.4.2172>][PMID: 12165547]
- [46] Ritter J, Seitz V, Balzer H, *et al.* Donor CD4 T Cell Diversity Determines Virus Reactivation in Patients After HLA-Matched Allogeneic Stem Cell Transplantation. *Am J Transplant* 2015; 15(8): 2170–9
[<https://doi.org/10.1111/ajt.13241>][PMID: 25873100]
- [47] Miconnet I, Marrau A, Farina A, *et al.* Large TCR diversity of virus-specific CD8 T cells provides the mechanistic basis for massive TCR renewal after antigen exposure. *J Immunol* 2011; 186(12): 7039–49
[<https://doi.org/10.4049/jimmunol.1003309>][PMID: 21555537]
- [48] van Heijst JWW, Ceberio I, Lipuma LB, *et al.* Quantitative assessment of T cell repertoire recovery after hematopoietic stem cell transplantation. *Nat Med* 2013; 19(3): 372–7
[<https://doi.org/10.1038/nm.3100>][PMID: 23435170]
- [49] Miles JJ, Elhassen D, Borg NA, *et al.* CTL recognition of a bulged viral peptide involves biased TCR selection. *J Immunol* 2005; 175(6): 3826–34
[<https://doi.org/10.4049/jimmunol.175.6.3826>][PMID: 16148129]
- [50] Rooney CM, Aguilar LK, Huls MH, Brenner MK, Heslop HE. Adoptive immunotherapy of EBV-associated malignancies with EBV-specific cytotoxic T-cell lines. *Curr Top Microbiol Immunol* 2001; 258: 221–9
[https://doi.org/10.1007/978-3-642-56515-1_14][PMID: 11443864]
- [51] Klarenbeek PL, Remmerswaal EBM, Berge IJM ten, *et al.* Deep sequencing of antiviral T-cell responses to HCMV and EBV in humans reveals a stable repertoire that is maintained for many years. *PLoS Pathog* 2012; 8(9): e1002889
[<https://doi.org/10.1371/journal.ppat.1002889>][PMID: 23028307]
- [52] Keller MD, Darko S, Lang H, *et al.* T-cell receptor sequencing demonstrates persistence of virus-specific T cells after antiviral immunotherapy. *Br J Haematol* 2019; 187(2): 206–18
[<https://doi.org/10.1111/bjh.16053>][PMID: 31219185]

- [53] Annels NE, Callan MF, Tan L, Rickinson AB. Changing patterns of dominant TCR usage with maturation of an EBV-specific cytotoxic T cell response. *J Immunol* 2000; 165(9): 4831–41 [https://doi.org/10.4049/jimmunol.165.9.4831][PMID: 11046006]
- [54] Iancu EM, Gannon PO, Laurent J, *et al.* Persistence of EBV antigen-specific CD8 T cell clonotypes during homeostatic immune reconstitution in cancer patients. *PLoS One* 2013; 8(10): e78686 [https://doi.org/10.1371/journal.pone.0078686][PMID: 24205294]
- [55] Hislop AD, Kuo M, Drake-Lee AB, *et al.* Tonsillar homing of Epstein-Barr virus-specific CD8+ T cells and the virus-host balance. *J Clin Invest* 2005; 115(9): 2546–55 [https://doi.org/10.1172/JCI24810][PMID: 16110323]
- [56] Wang G, Mudgal P, Wang L, *et al.* TCR repertoire characteristics predict clinical response to adoptive CTL therapy against nasopharyngeal carcinoma. *Oncoimmunology* 2021; 10(1): 1955545 [https://doi.org/10.1080/2162402X.2021.1955545][PMID: 34377592]
- [57] Hernández DM, Valderrama S, Gualtero S, *et al.* Loss of T-Cell Multifunctionality and TCR-V β Repertoire Against Epstein-Barr Virus Is Associated With Worse Prognosis and Clinical Parameters in HIV+ Patients. *Front Immunol* 2018; 9: 2291 [https://doi.org/10.3389/fimmu.2018.02291][PMID: 30337929]
- [58] Annels NE, Kalpoe JS, Bredius RGM, *et al.* Management of Epstein-Barr virus (EBV) reactivation after allogeneic stem cell transplantation by simultaneous analysis of EBV DNA load and EBV-specific T cell reconstitution. *Clin Infect Dis* 2006; 42(12): 1743–8 [https://doi.org/10.1086/503838][PMID: 16705581]
- [59] van Esser JW, van der Holt B, Meijer E, *et al.* Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. *Blood* 2001; 98(4): 972–8 [https://doi.org/10.1182/blood.V98.4.972][PMID: 11493441]
- [60] Toner K, Bollard CM, Dave H. T-cell therapies for T-cell lymphoma. *Cytotherapy* 2019; 21(9): 935–42 [https://doi.org/10.1016/j.jcyt.2019.04.058][PMID: 31320195]
- [61] Bingjie W, Lihong W, Yongjin S, Huihui L, Jinping O, Xi'nan C. The efficacy and safety of Epstein-Barr virus-specific antigen peptide-activated cytotoxic T-cells treatment for refractory or recurrent angioimmunoblastic T-cell lymphoma: A prospective clinical observational study. *Hematol Oncol* 2020; 38(3): 272–6 [https://doi.org/10.1002/hon.2726][PMID: 32083758]
- [62] Khanna R, Bell S, Sherritt M, *et al.* Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. *Proc Natl Acad Sci U S A* 1999; 96(18): 10391–6 [https://doi.org/10.1073/pnas.96.18.10391][PMID: 10468618]

- [63] Barrett AJ, Bollard CM. The coming of age of adoptive T-cell therapy for viral infection after stem cell transplantation. *Ann Transl Med* 2015; 3(5): 62
[<https://doi.org/10.3978/j.issn.2305-5839.2015.01.18>][PMID: 25992361]
- [64] Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. *Science* 1992; 257(5067): 238–41
[<https://doi.org/10.1126/science.1352912>][PMID: 1352912]
- [65] Moosmann A, Bigalke I, Tischer J, *et al.* Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. *Blood* 2010; 115(14): 2960–70
[<https://doi.org/10.1182/blood-2009-08-236356>][PMID: 20103780]
- [66] Icheva V, Kayser S, Wolff D, *et al.* Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation. *J Clin Oncol* 2013; 31(1): 39–48
[<https://doi.org/10.1200/JCO.2011.39.8495>][PMID: 23169501]
- [67] Xiang Z, Liu Y, Zheng J, *et al.* Targeted activation of human Vγ9Vδ2-T cells controls epstein-barr virus-induced B cell lymphoproliferative disease. *Cancer Cell* 2014; 26(4): 565–76
[<https://doi.org/10.1016/j.ccr.2014.07.026>][PMID: 25220446]
- [68] Linnerbauer S, Behrends U, Adhikary D, Witter K, Bornkamm GW, Mautner J. Virus and autoantigen-specific CD4+ T cells are key effectors in a SCID mouse model of EBV-associated post-transplant lymphoproliferative disorders. *PLoS Pathog* 2014; 10(5): e1004068
[<https://doi.org/10.1371/journal.ppat.1004068>][PMID: 24853673]
- [69] Smith C, Tsang J, Beagley L, *et al.* Effective treatment of metastatic forms of Epstein-Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy. *Cancer Res* 2012; 72(5): 1116–25
[<https://doi.org/10.1158/0008-5472.CAN-11-3399>][PMID: 22282657]
- [70] Meij P, van Esser JWJ, Niesters HGM, *et al.* Impaired recovery of Epstein-Barr virus (EBV)--specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease. *Blood* 2003; 101(11): 4290–7
[<https://doi.org/10.1182/blood-2002-10-3001>][PMID: 12576337]
- [71] Antsiferova O, Müller A, Rämer PC, *et al.* Adoptive transfer of EBV specific CD8+ T cell clones can transiently control EBV infection in humanized mice. *PLoS Pathog* 2014; 10(8): e1004333
[<https://doi.org/10.1371/journal.ppat.1004333>][PMID: 25165855]
- [72] Savoldo B, Huls MH, Liu Z, *et al.* Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. *Blood* 2002; 100(12): 4059–66
[<https://doi.org/10.1182/blood-2002-01-0039>][PMID: 12393655]
- [73] Bollard CM, Kuehnle I, Leen A, Rooney CM, Heslop HE. Adoptive immunotherapy for posttransplantation viral infections. *Biol Blood Marrow Transplant* 2004; 10(3): 143–55
[<https://doi.org/10.1016/j.bbmt.2003.09.017>][PMID: 14993880]

780 [74] van Dongen JJM, Langerak AW, Brüggemann M, *et al.* Design and standardization of PCR primers
 781 and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in
 782 suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936.
 783 Leukemia 2003; 17(12): 2257–317
 784 [<https://doi.org/10.1038/sj.leu.2403202>][PMID: 14671650]

Supporting information

S1 Fig. Identification of epitope-specific T cells. Scatter plots show frequency before and after multimer sort of the T cell product on day 9 of T cell clonotypes with a frequency above 0.1% in both populations. Each dot represents a single TCR clonotype. Red dots symbolize TCR clonotypes that pass a ternary exclusion criterion of at least ten times the multimer enrichment ratio for one multimer as compared with the other two and can, therefore, are identified as epitope-specific.

S2 Fig. Lymphoma diagnosis and relapse. (A) GeneScan analysis of T cell receptor gamma (TRG) and beta (TRB) demonstrated clonal T cell populations in the lymph node. (B) HTS of TCR β rearrangements of the lymph node permit identification of the lymphoma-specific TCR β sequence (in bold). (C) The lymphoma-specific TCR β sequence could be identified again in the recipient on day 60 after transplantation in peripheral blood.

S3 Fig. Enrichment of epitope-specific clonotypes after sorting on day 9. Frequencies of epitope-specific clonotypes (77 TCRs) is shown in unsorted CD8⁺ T cell product and MHC multimer-sorted sample. Clonotype frequency is displayed as a percentage from 0.01 (limit of detection) to 14.4637 by increasing colour depth. Each row represents one specific TCR rearrangement. Identified public TCR sequences (P1 and P2) published [28, 30] are highlighted in grey boxes. The most dominant clones (D 1-3) within each specificity are highlighted in pink boxes.

S1 Table. Patient characteristics and treatment. AITL: angioimmunoblastic T cell lymphoma; IgG: Immunoglobulin G; IgM: Immunoglobulin M; pos.: positive; neg.: negative; R-CHOP: Rituximab, Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone; R-ICE: Rituximab, Ifosfamide, Carboplatin, and Etoposide; Fc: fragment crystallizable region; PD: progressive disease; SD: stable disease; allo-SCT: allogeneic stem cell transplantation; ATG: antithymocyte globulin; HLA: human leukocyte antigen; CMV: Cytomegalovirus; EBV: Epstein-Barr Virus; DLI: donor lymphocyte infusion; ATCT: adoptive T cell transfer; GvHD: Graft-versus-Host Disease; CsA: cyclosporin; HSV-1: Herpes-Simplex Virus-1.

811 **S2 Table. EPL-specific T cells.** TCR β VJ ID: identification number for TCR β variable-joining
812 rearrangement, AA: amino acid.

813 **S3 Table. RAK-specific T cells.** TCR β VJ ID: identification number for TCR β variable-joining
814 rearrangement, AA: amino acid.

815 **S4 Table. HPV-specific T cells.** TCR β VJ ID: identification number for TCR β variable-joining
816 rearrangement, AA: amino acid.

817 **S5 Table. Presence of EPL-, RAK-, and HPV-specific T cells in different samples.**

Fig1

A

B

bioRxiv preprint doi: <https://doi.org/10.1101/2021.12.16.473087>; this version posted December 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

C

Fig2

Fig3

A

B

dominant clonotypes (D)

D#	donor PBMC	T cell product	sort day 9	patient				CDR3 sequence	epitope
				day 60	day 120	day 180	day 232		
D1	0.242	1.959	13.732	0.000	3.474	2.499	0.482	CASRDRVGSEAFF	EPL
D2	0.347	7.862	18.947	0.000	1.969	2.169	0.532	CASSTSRGAGNTIYF	RAK
D3	0.605	14.464	38.810	0.000	1.011	0.946	0.135	CASGTEAFF	HPV

public clonotypes (P)

P#	donor PBMC	T cell product	sort day 9	patient				CDR3 sequence	epitope
				day 60	day 120	day 180	day 232		
P1	0.019	0.338	2.081	0.000	0.492	0.219	0.154	CASSTGDSNQPQHF	EPL
P2	0.016	0.261	1.053	0.000	0.058	0.031	0.000	CASSLNTEAFF	RAK

Fig4